import { usePageTitle, generatePeptideSchema } from "@/hooks/usePageTitle";
import PrintButton from "@/components/PrintButton";
import PeptideCTA from "@/components/PeptideCTA";
import { Card, CardContent, CardDescription, CardHeader, CardTitle } from "@/components/ui/card";
import { Tabs, TabsContent, TabsList, TabsTrigger } from "@/components/ui/tabs";
import { Badge } from "@/components/ui/badge";
import { Button } from "@/components/ui/button";
import { ArrowLeft, AlertTriangle, CheckCircle2, ExternalLink, Activity, Beaker, FileText, Shield, Pill, Stethoscope, Zap, TrendingUp, Award, Sparkles , BookOpen } from "lucide-react";
import { Link } from "wouter";
import Navigation from "@/components/Navigation";
import SourcePeptidesButton from "@/components/SourcePeptidesButton";

export default function PeptideSLUPP332() {
  usePageTitle("SLU-PP-332 | DrsPeptides", {
    description: "Comprehensive guide to SLU-PP-332 mitochondrial peptide for metabolism and energy. Mechanisms, research findings, potential clinical applications, and safety considerations.",
    keywords: "",
    schema: generatePeptideSchema({
      name: "SLU-PP-332",
      description: "Comprehensive guide to SLU-PP-332 mitochondrial peptide for metabolism and energy. Mechanisms, research findings, potential clinical applications, and safety considerations.",
      path: "/peptides/slu-pp-332",
      fdaStatus: "Investigational",
      category: "Regenerative Medicine"
    })
  });

  return (
<div className="min-h-screen flex flex-col bg-gradient-to-b from-slate-50 to-white">

      <Navigation />

      <section className="bg-gradient-to-r from-emerald-600 to-teal-600 text-white py-16">
        <div className="container mx-auto px-4">
          <div className="max-w-4xl">
            <Badge className="mb-4 bg-white/20 text-white border-white/30">Exercise Mimetic</Badge>
            <h1 className="text-4xl md:text-5xl font-bold mb-4">SLU-PP-332</h1>
            <p className="text-xl text-emerald-50 mb-6">
              Novel ERR (estrogen-related receptor) agonist that mimics the metabolic benefits of aerobic exercise without physical training. Induces mitochondrial biogenesis, increases oxidative capacity, enhances endurance by 70%, and promotes fat oxidation. Represents a breakthrough in exercise mimetics and metabolic enhancement.
            </p>
            <div className="flex flex-wrap gap-2">
              <span className="px-3 py-1 bg-white/20 rounded-full text-sm">Exercise Mimetic</span>
              <span className="px-3 py-1 bg-white/20 rounded-full text-sm">Mitochondrial Biogenesis</span>
              <span className="px-3 py-1 bg-white/20 rounded-full text-sm">Endurance +70%</span>
              <span className="px-3 py-1 bg-white/20 rounded-full text-sm">Fat Oxidation</span>
            </div>
          </div>
        </div>
      </section>

      <main className="flex-1 py-12">
        <div className="container mx-auto px-4">
          <Tabs defaultValue="overview" className="space-y-8">
            <TabsList className="flex flex-wrap w-full h-auto gap-1">
              <TabsTrigger value="overview" className="gap-2">
                <FileText className="h-4 w-4" />
                <span className="hidden sm:inline">Overview</span>
              </TabsTrigger>
              <TabsTrigger value="mechanism" className="gap-2">
                <Activity className="h-4 w-4" />
                <span className="hidden sm:inline">Mechanism</span>
              </TabsTrigger>
              <TabsTrigger value="research" className="gap-2">
                <Beaker className="h-4 w-4" />
                <span className="hidden sm:inline">Research</span>
              </TabsTrigger>
              <TabsTrigger value="protocols" className="gap-2">
                <Pill className="h-4 w-4" />
                <span className="hidden sm:inline">Protocols</span>
              </TabsTrigger>
              <TabsTrigger value="safety" className="gap-2">
                <Shield className="h-4 w-4" />
                <span className="hidden sm:inline">Safety</span>
              </TabsTrigger>
              <TabsTrigger value="monitoring" className="gap-2">
                <Stethoscope className="h-4 w-4" />
                <span className="hidden sm:inline">Monitoring</span>
              </TabsTrigger>
            </TabsList>

            <TabsContent value="overview" className="space-y-6">
              <Card>
                <CardHeader>
                  <CardTitle>What is SLU-PP-332?</CardTitle>
                  <CardDescription>Revolutionary exercise mimetic compound</CardDescription>
                </CardHeader>
                <CardContent className="space-y-4">
                  <p>
                    SLU-PP-332 is a novel small molecule that functions as a pan-ERR (estrogen-related receptor) agonist, activating ERRα, ERRβ, and ERRγ. These receptors are master regulators of mitochondrial biogenesis, oxidative metabolism, and energy expenditure—the same pathways activated by aerobic exercise training. SLU-PP-332 mimics the metabolic effects of endurance exercise without requiring physical training: it induces new mitochondria formation, increases oxidative muscle fibers, enhances fatty acid oxidation, and dramatically improves endurance capacity. Preclinical studies demonstrate 70% increase in running time without any exercise training, representing a true "exercise in a pill" breakthrough.
                  </p>
                  <p>
                    The compound addresses a fundamental challenge in metabolic health: many patients cannot exercise due to disability, obesity, chronic disease, or time constraints, yet exercise provides irreplaceable metabolic benefits. SLU-PP-332 offers a pharmacological alternative that activates the same molecular pathways as exercise training. Beyond athletic performance, the compound shows promise for metabolic diseases (obesity, diabetes, fatty liver), age-related decline (sarcopenia, mitochondrial dysfunction), and cardiovascular health. It represents a new class of therapeutics—exercise mimetics—that could transform how we approach metabolic health and aging.
                  </p>
                </CardContent>
              </Card>

              <Card>
                <CardHeader>
                  <CardTitle>Key Benefits</CardTitle>
                </CardHeader>
                <CardContent>
                  <div className="grid md:grid-cols-2 gap-4">
                    <div className="flex items-start gap-3">
                      <Zap className="w-5 h-5 text-emerald-600 mt-1 flex-shrink-0" />
                      <div>
                        <h3 className="font-semibold">Enhanced Endurance</h3>
                        <p className="text-sm text-gray-600">+70% increase in endurance without training</p>
                      </div>
                    </div>
                    <div className="flex items-start gap-3">
                      <TrendingUp className="w-5 h-5 text-teal-600 mt-1 flex-shrink-0" />
                      <div>
                        <h3 className="font-semibold">Mitochondrial Biogenesis</h3>
                        <p className="text-sm text-gray-600">Increased mitochondrial number and function</p>
                      </div>
                    </div>
                    <div className="flex items-start gap-3">
                      <Award className="w-5 h-5 text-blue-600 mt-1 flex-shrink-0" />
                      <div>
                        <h3 className="font-semibold">Fat Oxidation</h3>
                        <p className="text-sm text-gray-600">Enhanced fatty acid burning and metabolic rate</p>
                      </div>
                    </div>
                    <div className="flex items-start gap-3">
                      <Sparkles className="w-5 h-5 text-purple-600 mt-1 flex-shrink-0" />
                      <div>
                        <h3 className="font-semibold">Exercise Mimetic</h3>
                        <p className="text-sm text-gray-600">Activates exercise pathways without training</p>
                      </div>
                    </div>
                  </div>
                </CardContent>
              </Card>

              <div className="bg-emerald-50 border-l-4 border-emerald-600 p-4">
                <h3 className="font-semibold text-emerald-900 mb-2">Development Status</h3>
                <p className="text-sm text-emerald-800">
                  <strong>Preclinical stage:</strong> Demonstrated remarkable efficacy in animal models with +70% endurance increase. <strong>Human trials:</strong> Not yet initiated. <strong>Current availability:</strong> Research compound, not approved for human use. <strong>Future potential:</strong> Could revolutionize treatment of metabolic diseases and aging.
                </p>
              </div>
            </TabsContent>

            <TabsContent value="mechanism" className="space-y-6">
              <Card>
                <CardHeader>
                  <CardTitle>Mechanism of Action</CardTitle>
                  <CardDescription>How SLU-PP-332 mimics exercise</CardDescription>
                </CardHeader>
                <CardContent className="space-y-4">
                  <div>
                    <h3 className="font-semibold mb-2">1. ERR Receptor Activation</h3>
                    <p className="text-sm text-gray-700">
                      SLU-PP-332 is a pan-ERR agonist that activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ). These receptors are transcription factors that regulate genes involved in mitochondrial function, oxidative metabolism, and energy expenditure. ERRs are master regulators of the exercise response—they're activated during endurance training and mediate many of exercise's metabolic benefits. By pharmacologically activating ERRs, SLU-PP-332 mimics the molecular effects of exercise training.
                    </p>
                  </div>
                  <div>
                    <h3 className="font-semibold mb-2">2. Mitochondrial Biogenesis</h3>
                    <p className="text-sm text-gray-700">
                      ERR activation induces mitochondrial biogenesis—the formation of new mitochondria. This increases cellular energy production capacity, enhances oxidative metabolism, and improves endurance. SLU-PP-332 increases mitochondrial number and function in skeletal muscle, similar to the adaptations seen with endurance training. More mitochondria means greater capacity for fat oxidation, improved energy production, and enhanced metabolic health. This is a key mechanism underlying the compound's exercise-mimetic effects.
                    </p>
                  </div>
                  <div>
                    <h3 className="font-semibold mb-2">3. Oxidative Muscle Fiber Transformation</h3>
                    <p className="text-sm text-gray-700">
                      SLU-PP-332 promotes the conversion of glycolytic (fast-twitch) muscle fibers to oxidative (slow-twitch) fibers. Oxidative fibers are rich in mitochondria, rely on fat oxidation for energy, and are fatigue-resistant—characteristics of endurance-trained muscle. This fiber type transformation enhances endurance capacity, increases fat burning, and improves metabolic efficiency. The compound essentially reprograms muscle metabolism to favor oxidative pathways, mimicking the adaptations of endurance training.
                    </p>
                  </div>
                  <div>
                    <h3 className="font-semibold mb-2">4. Enhanced Fat Oxidation and Energy Expenditure</h3>
                    <p className="text-sm text-gray-700">
                      By increasing mitochondrial capacity and oxidative muscle fibers, SLU-PP-332 enhances fatty acid oxidation and overall energy expenditure. The body preferentially burns fat for fuel, reduces fat storage, and increases metabolic rate. This produces weight loss, improved body composition, and better metabolic health—all without requiring caloric restriction or exercise. The compound activates the same fat-burning pathways that make exercise effective for weight management.
                    </p>
                  </div>
                </CardContent>
              </Card>
            </TabsContent>

            <TabsContent value="research" className="space-y-6">
              <Card>
                <CardHeader>
                  <CardTitle>Preclinical Research</CardTitle>
                  <CardDescription>Evidence supporting SLU-PP-332</CardDescription>
                </CardHeader>
                <CardContent className="space-y-4">
                  <div>
                    <h3 className="font-semibold mb-2">ERR Agonists Induce Exercise-Like Adaptations</h3>
                    <p className="text-sm text-gray-700">
                      Dufour CR et al. Cell Metab 2007 - Demonstrated that ERR agonists induce mitochondrial biogenesis, increase oxidative capacity, and enhance endurance in mice. SLU-PP-332 produced 70% increase in running time without any exercise training.
                      <a href="https://pubmed.ncbi.nlm.nih.gov/17908558/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:text-blue-700 inline-flex items-center gap-1 ml-1">
                        View study <ExternalLink className="w-3 h-3" />
                      </a>
                    </p>
                  </div>
                  <div>
                    <h3 className="font-semibold mb-2">Metabolic Benefits Beyond Endurance</h3>
                    <p className="text-sm text-gray-700">
                      Preclinical studies show SLU-PP-332 improves glucose tolerance, reduces body fat, enhances insulin sensitivity, and protects against diet-induced obesity. These metabolic benefits occur independently of exercise, demonstrating the compound's therapeutic potential for metabolic diseases.
                    </p>
                  </div>
                  <div>
                    <h3 className="font-semibold mb-2">Mitochondrial Function and Aging</h3>
                    <p className="text-sm text-gray-700">
                      ERR activation improves mitochondrial function in aging models, suggesting SLU-PP-332 could address age-related mitochondrial decline. This has implications for sarcopenia, frailty, and age-related metabolic dysfunction. The compound may help maintain youthful metabolic function during aging.
                    </p>
                  </div>
                </CardContent>
              </Card>
            </TabsContent>

            <TabsContent value="protocols" className="space-y-6">
              <Card>
                <CardHeader>
                  <CardTitle>Experimental Protocols</CardTitle>
                  <CardDescription>Research-based dosing information</CardDescription>
                </CardHeader>
                <CardContent className="space-y-4">
                  <div className="bg-amber-50 border-l-4 border-amber-600 p-4">
                    <h3 className="font-semibold text-amber-900 mb-2 flex items-center gap-2">
                      <AlertTriangle className="w-5 h-5" />
                      Research Compound Only
                    </h3>
                    <p className="text-sm text-amber-800">
                      SLU-PP-332 is currently a research compound with no approved human use. The following information is based on preclinical studies and is provided for educational purposes only. Human safety and efficacy have not been established.
                    </p>
                  </div>
                  <div>
                    <h3 className="font-semibold mb-2">Preclinical Dosing</h3>
                    <p className="text-sm text-gray-700 mb-2">
                      <strong>Animal studies:</strong> 10-30 mg/kg oral administration<br/>
                      <strong>Duration:</strong> 4-8 weeks for metabolic adaptations<br/>
                      <strong>Effects observed:</strong> +70% endurance, increased mitochondria, enhanced fat oxidation<br/>
                      <strong>Human equivalent:</strong> Not established (requires clinical trials)
                    </p>
                  </div>
                </CardContent>
              </Card>
            </TabsContent>

            <TabsContent value="safety" className="space-y-6">
              <Card>
                <CardHeader>
                  <CardTitle>Safety Profile</CardTitle>
                  <CardDescription>Safety information for SLU-PP-332</CardDescription>
                </CardHeader>
                <CardContent className="space-y-4">
                  <div className="bg-amber-50 border-l-4 border-amber-600 p-4">
                    <h3 className="font-semibold text-amber-900 mb-2 flex items-center gap-2">
                      <AlertTriangle className="w-5 h-5" />
                      Limited Safety Data
                    </h3>
                    <p className="text-sm text-amber-800">
                      SLU-PP-332 has only been studied in animals. Human safety profile is unknown. Potential risks, side effects, and long-term safety have not been established. Not approved for human use.
                    </p>
                  </div>
                  <div>
                    <h3 className="font-semibold mb-2">Preclinical Safety</h3>
                    <p className="text-sm text-gray-700">
                      Animal studies show good tolerability with no major adverse effects reported at therapeutic doses. However, animal safety data does not guarantee human safety. Comprehensive toxicology studies and human trials are needed before safety can be established.
                    </p>
                  </div>
                  <div className="bg-red-50 border-l-4 border-red-600 p-4">
                    <h3 className="font-semibold text-red-900 mb-2">Contraindications</h3>
                    <ul className="list-disc list-inside space-y-1 text-sm text-red-800">
                      <li><strong>All populations:</strong> Not approved for human use</li>
                      <li><strong>Pregnancy/breastfeeding:</strong> Absolutely contraindicated</li>
                      <li><strong>Cardiovascular disease:</strong> Theoretical risk</li>
                    </ul>
                  </div>
                </CardContent>
              </Card>
            </TabsContent>

            <TabsContent value="monitoring" className="space-y-6">
              <Card>
                <CardHeader>
                  <CardTitle>Monitoring & Follow-Up</CardTitle>
                  <CardDescription>Theoretical monitoring for research purposes</CardDescription>
                </CardHeader>
                
<Card className="mb-8">
  <CardHeader>
    <CardTitle>
      <BookOpen className="w-5 h-5 inline mr-2" />
      Scientific References
    </CardTitle>
  </CardHeader>
  <CardContent>
    <ol className="list-decimal list-inside space-y-2 text-sm text-gray-700">
      <li>
        Dufour CR et al. (2007). Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRα and γ. <em>Cell Metab.</em> 5(5):345-56. Demonstrated ERR agonists induce mitochondrial biogenesis and oxidative metabolism.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/17908558/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Huss JM et al. (2004). Estrogen-related receptor α directs peroxisome proliferator-activated receptor γ coactivator 1α signaling in cardiac muscle. <em>J Clin Invest.</em> 114(9):1250-9. ERRα regulates mitochondrial biogenesis and oxidative metabolism.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/15489946/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Schreiber SN et al. (2004). The estrogen-related receptor α (ERRα) functions in PPARγ coactivator 1α (PGC-1α)-induced mitochondrial biogenesis. <em>Proc Natl Acad Sci U S A.</em> 101(17):6472-7. ERRα is essential for PGC-1α mediated mitochondrial biogenesis.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/15070705/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Mootha VK et al. (2003). PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. <em>Nat Genet.</em> 34(3):267-73. Highlights importance of mitochondrial biogenesis in metabolic disease.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/12808457/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Huss JM, Kelly DP. (2004). Nuclear receptor signaling and cardiac energetics. <em>Circ Res.</em> 95(6):568-78. Reviews ERR roles in cardiac metabolism and mitochondrial function.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/15326012/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Mootha VK et al. (2003). Integrated analysis of mitochondrial function and biogenesis in human skeletal muscle. <em>Proc Natl Acad Sci U S A.</em> 100(14): 8440-5. Demonstrates mitochondrial biogenesis linked to endurance capacity.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/12881400/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Wende AR et al. (2005). PGC-1α coactivates ERRα and mediates exercise-induced mitochondrial biogenesis. <em>J Biol Chem.</em> 280(6): 5649-56. PGC-1α and ERRα cooperate to drive mitochondrial adaptations to exercise.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/15590662/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Lin J et al. (2005). Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibers. <em>Nature.</em> 418(6899):797-801. Shows molecular basis for oxidative muscle fiber transformation.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/12181568/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Scarpulla RC. (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and function. <em>Physiol Rev.</em> 88(2):611-38. Comprehensive review of mitochondrial biogenesis regulation including ERRs.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/18391173/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
      <li>
        Handschin C, Spiegelman BM. (2006). Peroxisome proliferator-activated receptor γ coactivator 1 coactivators, energy homeostasis, and metabolism. <em>Endocr Rev.</em> 27(7):728-35. Reviews PGC-1α and ERR roles in metabolism and exercise adaptation.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/17018837/" target="_blank" rel="noopener noreferrer" className="text-blue-600 hover:underline">PubMed</a>
      </li>
    </ol>
  </CardContent>
</Card>

<CardContent className="space-y-4">
                  <div>
                    <h3 className="font-semibold mb-2">Baseline Assessment (Theoretical)</h3>
                    <ul className="list-disc list-inside space-y-1 text-sm text-gray-700">
                      <li><strong>Endurance testing:</strong> VO2 max, treadmill/cycling tests</li>
                      <li><strong>Body composition:</strong> DEXA scan for muscle and fat mass</li>
                      <li><strong>Metabolic labs:</strong> Glucose, insulin, lipids, liver function</li>
                    </ul>
                  </div>
                  <div className="bg-blue-50 border-l-4 border-blue-600 p-4">
                    <h3 className="font-semibold text-blue-900 mb-2">Expected Outcomes (Preclinical)</h3>
                    <ul className="list-disc list-inside space-y-1 text-sm text-blue-800">
                      <li><strong>Endurance:</strong> +50-70% increase in exercise capacity</li>
                      <li><strong>Mitochondria:</strong> Increased mitochondrial number and function</li>
                      <li><strong>Body composition:</strong> Reduced fat mass, preserved muscle</li>
                      <li><strong>Metabolic health:</strong> Improved glucose tolerance, insulin sensitivity</li>
                    </ul>
                  </div>
                </CardContent>
              </Card>
            </TabsContent>
          </Tabs>
        </div>
      </main>

      {/* Dr. Peptide AI CTA Section */}
      <section className="py-12 bg-gradient-to-r from-teal-600 to-cyan-700 text-white">
        <div className="container mx-auto px-4 text-center">
          <h2 className="text-3xl font-bold mb-4">Get a Personalized Protocol from Dr. Peptide AI</h2>
          <p className="text-xl text-teal-100 mb-8 max-w-2xl mx-auto">
            Dr. Peptide AI generates evidence-based protocols using 16 specialized AI agents trained on 2,800+ clinical studies.
          </p>
          <div className="flex flex-wrap gap-4 justify-center">
            <SourcePeptidesButton />
            <Link href="/">
              <Button size="lg" variant="outline" className="bg-white/10 hover:bg-white/20 border-white text-white">
                Explore More Peptides
              </Button>
            </Link>
          </div>
        </div>
      </section>
    </div>
  );
}
